Profile data is unavailable for this security.
About the company
Infant Bacterial Therapeutics AB is a Sweden-based company, which is primarily involved in the pharmaceutical industry. The Company develops drugs that meet the needs of the premature infant. The Company’s focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.
- Revenue in SEK (TTM)0.00
- Net income in SEK-32.15m
- Incorporated--
- Employees8.00
- LocationInfant Bacterial Therapeutics ABGamla Brogatan 11STOCKHOLM 111 20SwedenSWE
- Phone+46 841014555
- Websitehttp://ibtherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bonesupport Holding AB | 98.37m | -181.71m | 1.46bn | 72.00 | -- | 5.89 | -- | 14.36 | -3.55 | -3.55 | 1.92 | 4.63 | 0.2568 | 0.6216 | 3.67 | 1,366,195.00 | -47.43 | -- | -54.64 | -- | 85.54 | -- | -184.73 | -- | 4.65 | -15,022.42 | 0.0519 | -- | -25.27 | -- | -36.89 | -- | -- | -- |
| Orphazyme A/S | -142.39bn | -142.39bn | 1.55bn | 57.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -81.93 | -- | -- | -- |
| Q linea AB | 1.24m | -140.72m | 1.58bn | 56.00 | -- | 3.29 | -- | 1,265.72 | -8.00 | -8.00 | 0.072 | 20.66 | 0.0038 | -- | 59.14 | 23,433.96 | -43.54 | -- | -47.79 | -- | -6,547.42 | -- | -11,330.27 | -- | -- | -248.95 | 0.0021 | -- | -28.93 | -- | -89.09 | -- | -- | -- |
| Nuevolution AB (publ) | 16.78m | -90.44m | 1.60bn | 47.00 | -- | 15.25 | -- | 95.36 | -1.91 | -1.91 | 0.3502 | 2.12 | 0.1309 | -- | 1.00 | 342,346.90 | -70.58 | -- | -83.60 | -- | -- | -- | -539.12 | -- | -- | -78.23 | 0.166 | -- | -- | -- | -- | -- | -- | -- |
| Alligator Bioscience AB | 26.22m | -152.22m | 1.87bn | 56.00 | -- | 4.40 | -- | 71.19 | -2.13 | -2.13 | 0.3673 | 5.94 | 0.0492 | -- | 19.28 | 476,800.00 | -28.53 | -- | -29.99 | -- | -- | -- | -580.47 | -- | -- | -- | 0.0465 | -- | -52.60 | -- | -135.33 | -- | -- | -- |
| Calliditas Therapeutics AB | 0.00 | -136.37m | 1.91bn | 13.00 | -- | 3.64 | -- | -- | -6.64 | -6.64 | 0.00 | 16.44 | 0.00 | -- | -- | 0.00 | -40.82 | -- | -44.93 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -52.14 | -- | -- | -- |
| Nordic Nanovector ASA | 0.00 | -368.53m | 2.24bn | 45.00 | -- | 3.79 | -- | -- | -6.75 | -6.75 | 0.00 | 8.86 | 0.00 | -- | -- | 0.00 | -54.52 | -34.38 | -62.03 | -38.09 | -- | -- | -- | -73,984.18 | -- | -- | 0.0125 | -- | -100.00 | -- | -14.96 | -- | 48.77 | -- |
| Infant Bacterial Therapeutics AB | 0.00 | -32.15m | 2.56bn | 8.00 | -- | 4.71 | -- | -- | -2.86 | -2.86 | 0.00 | 49.53 | 0.00 | -- | -- | 0.00 | -5.55 | -17.29 | -5.61 | -18.00 | -- | -- | -- | -28,727.13 | -- | -32.95 | 0.00 | -- | -100.00 | -- | -12.31 | -- | -- | -- |
| Orexo AB | 817.70m | 177.90m | 2.58bn | 131.00 | 14.28 | 5.06 | 12.33 | 3.08 | 5.09 | 5.09 | 23.38 | 14.37 | 0.6806 | 0.7984 | 3.48 | 6,338,760.00 | 14.81 | -1.44 | 23.70 | -2.10 | 81.81 | 77.80 | 21.76 | -2.28 | 1.81 | -- | 0.4375 | -- | 21.66 | 12.77 | 494.40 | -- | -43.66 | -- |
| Immunovia AB (publ) | 286.60k | -95.60m | 2.83bn | 46.00 | -- | 7.55 | -- | 10,151.55 | -5.02 | -5.02 | 0.015 | 22.26 | 0.0008 | -- | 16.86 | 6,368.89 | -26.39 | -17.94 | -27.94 | -18.78 | -15,583.15 | -5,071.06 | -33,355.42 | -13,304.19 | -- | -- | 0.0729 | -- | 123.28 | -22.36 | -91.32 | -- | 81.72 | -- |
| Camurus AB | 53.18m | -266.03m | 3.50bn | 103.00 | -- | 6.24 | -- | 65.86 | -6.28 | -6.28 | 1.25 | 11.70 | 0.0934 | 0.8918 | 15.82 | 565,702.10 | -46.70 | -- | -56.93 | -- | 84.44 | -- | -500.29 | -- | 3.67 | -573.05 | 0.0473 | -- | -9.18 | -- | -23.14 | -- | -- | -- |
| IRLAB Therapeutics AB | 18.00k | -75.97m | 3.56bn | 26.00 | -- | 18.34 | -- | 198,033.60 | -1.93 | -1.93 | 0.0005 | 4.84 | 0.0001 | -- | 0.004 | 720.00 | -41.94 | -- | -44.95 | -- | -- | -- | -422,055.60 | -- | -- | -274.25 | 0.0285 | -- | -83.49 | -- | -31.79 | -- | -- | -- |
| Oriola Oyj | 16.60bn | 118.04m | 3.80bn | 2.63k | 33.38 | 2.33 | 9.34 | 0.2352 | 0.0607 | 0.0607 | 8.60 | 0.8689 | 1.58 | 5.21 | 7.36 | 576,903.20 | 1.12 | 3.51 | 3.77 | 11.31 | 22.34 | 21.43 | 0.711 | 2.17 | 0.359 | 6.04 | 0.5902 | 47.58 | 1.60 | -0.8477 | -51.15 | -5.89 | -5.36 | -- |
Data as of Jun 17 2019. Currency figures normalised to Infant Bacterial Therapeutics AB's reporting currency: Swedish Krona SEK
34.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 31 Dec 2018 | 1.05m | 9.70% |
| Swedbank Robur Fonder ABas of 31 May 2019 | 660.69k | 6.09% |
| AMF Fonder ABas of 31 Dec 2018 | 501.59k | 4.62% |
| Tredje AP-fondenas of 31 Dec 2018 | 415.64k | 3.83% |
| Andra AP-fondenas of 31 Dec 2018 | 263.50k | 2.43% |
| Nordic Cross Asset Management ABas of 13 Jun 2019 | 212.74k | 1.96% |
| Norges Bank Investment Managementas of 31 Dec 2018 | 205.04k | 1.89% |
| Catella Fondf�rvaltning ABas of 31 May 2019 | 183.08k | 1.69% |
| Norron ABas of 30 Apr 2019 | 151.34k | 1.40% |
| AXA Investment Managers (Paris) SAas of 31 Dec 2018 | 85.00k | 0.78% |
More ▼
Data from 31 Dec 2018 - 13 Jun 2019Source: FactSet Research Systems Inc.
